If I had to pick one for the next 30 days, I’d choose Amylyx Pharmaceuticals (AMLX) — not because it is the safest name, but because it has the clearest near-term binary catalyst.
The stock has already exploded higher, so chasing momentum here is risky. But the real story is still ahead: Amylyx expects Phase 3 LUCIDITY results for avexitide in late August or early September. A positive readout could materially change the company’s valuation and potentially support a 2027 commercial launch.
That makes AMLX fundamentally different from simply buying a beaten-down stock like Adobe or Intuit.
My choice: 🔥 Momentum, with a catalyst-driven setup.
The key is position sizing — this is biotech, so one clinical result can create either a breakout or a brutal reversal.
@TigerPicks [真香]
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
- dimzy5·08-19 20:12Market already priced in a lot of success here. Binary setup, sure, but after this run the downside on a miss feels nastier than the upside.LikeReport